Opko Health (OPK) Getting Somewhat Positive Press Coverage, Accern Reports
Press coverage about Opko Health (NASDAQ:OPK) has trended somewhat positive on Sunday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Opko Health earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.0236362226809 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Pharmaceutical Co Eloxx Raised $8M (nocamels.com)
- What Are the Numbers Saying About OPKO Health Inc (OPK)? – Danville Daily (danvilledaily.com)
- Pharmaceutical Co Eloxx Raises $8M (nocamels.com)
- OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017 (finance.yahoo.com)
- OPKO Health, Inc. – Value Analysis (NASDAQ:OPK) : August 4, 2017 (finance.yahoo.com)
A number of equities research analysts have commented on the stock. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. BidaskClub raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a research report on Friday, June 16th. Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a research report on Monday, June 12th. Finally, Barrington Research increased their price objective on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $14.72.
Shares of Opko Health (OPK) traded up 0.81% on Friday, hitting $6.20. 4,107,604 shares of the stock traded hands. The firm’s market cap is $3.47 billion. The firm’s 50-day moving average is $6.48 and its 200 day moving average is $7.40. Opko Health has a 12-month low of $5.99 and a 12-month high of $12.15.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $296.10 million for the quarter, compared to analysts’ expectations of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) EPS. Equities research analysts forecast that Opko Health will post ($0.20) EPS for the current fiscal year.
In related news, Vice Chairman Jane Ph D. Hsiao purchased 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was acquired at an average price of $6.97 per share, for a total transaction of $278,800.00. Following the completion of the purchase, the insider now owns 24,723,133 shares in the company, valued at $172,320,237.01. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Lerner purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was bought at an average price of $6.31 per share, with a total value of $63,100.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 2,856,000 shares of company stock valued at $18,990,617. Insiders own 40.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Opko Health (OPK) Getting Somewhat Positive Press Coverage, Accern Reports” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/06/opko-health-opk-getting-somewhat-positive-press-coverage-accern-reports.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.